Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone

Antiviral Therapy

Volumn 14, Issue 1, 2009, Pages 93-97

  Flandre, Philippe ^a,b   Delaugerre, Constance ^c   Ghosn, Jade ^c,d   Chaix, Marie Laure ^c   Horbari, Andrzej ^e   Girard, Pierre Marie ^f   Gladysz, Andrzej ^g   Cohen Codar, Isabelle ^h   Ngo Van, Philippe ^h   Taburet, Anne Marie ^d   Rouzioux, Christine ^c   Delfraissy, Jean François ^d  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d BICÊTRE HOSPITAL   (France)

^e National AIDS Centre   (Poland)

^f HÔPITAL SAINT ANTOINE   (France)

^g Kliniczny Chorb Zakanych   (Poland)

^h Abbott   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; TIPRANAVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MEDICATION ADHERENCE; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; VIRAL LOAD;

EID: 61849090321     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827-843.
2. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735-1744.
3. Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001; 15:2441-2444.
4. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998; 339:1261-1268.
5. Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med 1998; 339:1269-1276.
6. Campo RE, Lalanne R, Tanner TJ, et al. Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS 2005; 19:447-449.
7. Kahlert C, Hupfer M, Wagels T, et al. Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection. AIDS 2004; 18:955-957.
8. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006; 296:806-814.
9. Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS 2004; 18:775-779.
10. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046.
11. Delfraissy JF, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in aritiretroviral-naive HIV-infected patients. AIDS 2008; 22:385-393.
12. Lepri AC, Miller V, Phillips AN, Rabenau H, Sabin CA, Staszewski S. The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load. AIDS 2001; 15:47-54.
13. Maggiolo F, Mighorino M, Pirali A, Pravettoni G, Caprioli S, Suter F. Duration of viral suppression in patients on stable therafy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment. J Acquir Immune Defic Syndr 2000; 25:36-43.
14. Raffi F, Katlama C, Saag M, et al. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin Infect Dis 2006; 42:870-877.
15. McGrath D, Wirtz V, Yang R, Mathew M, Rightmire A, Schnittman S and the BMS A1424089 Study Group. Antiviral efficacy and emergent PI substitutions in treatment-naive subjects receiving atazanavir +/- ritonavir-based HAART in subtype B and non-type B HIV-1 infection. Antivir Ther 2007; 12S90.
16. Flandre P, Marcelin A, Masquelier B, et al. Impact of HIV-1 subtype in selecting mutations associated with response to boosted tipranavir in HIV-1 infected protease inhibitor experienced patients. Antivir Ther 2007; 12S83.
17. King MS, Brun SC, Kempf DJ. Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis 2005; 191:2046-2052.
18. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95 %. J Acquir Immune Defic Syndr 2007; 45:4-8.
19. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.